KAYLA WEAVER: Open Payments
NPI 1003110081 · ATHENS, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,533 in 121 payments from 20 companies in 2025. Trend: 2023 $1,668 · 2024 $1,533 · 2025 $2,533
Food & beverage: $2,456Education: $77
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 31 | $579 |
| Janssen Biotech, Inc. | 10 | $349 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 16 | $196 |
| Ipsen Biopharmaceuticals, Inc | 5 | $188 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $185 |
| Ardelyx, Inc. | 12 | $160 |
| Janssen Scientific Affairs, LLC | 1 | $126 |
| Regeneron Healthcare Solutions, Inc. | 5 | $118 |
| QOL Medical, LLC | 4 | $99 |
| GENZYME CORPORATION | 4 | $92 |
Products named: TREMFYA, DUPIXENT, XIFAXAN, IQIRVO, IBSRELA, RINVOQ, ENTYVIO, LINZESS.
Industry payments across GA — which companies pay providers there.
